These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26822493)

  • 1. Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.
    Bliden KP; Tantry US; Gesheff MG; Franzese CJ; Pandya S; Toth PP; Mathew DP; Chaudhary R; Gurbel PA
    J Interv Cardiol; 2016 Apr; 29(2):168-78. PubMed ID: 26822493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging.
    Kang SJ; Cho YR; Park GM; Ahn JM; Han SB; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Mintz GS; Park SJ
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1183-90. PubMed ID: 24229771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological characteristics of homogeneous and nonhomogeneous tissue of in-stent restenosis visualized by optical coherence tomography.
    Itoh T; Fusazaki T; Kimura T; Oikawa H; Sasou S; Ishikawa Y; Goto I; Komuro K; Nakajima S; Koeda Y; Kaneko K; Nishiyama O; Nakamura M; Morino Y
    Coron Artery Dis; 2015 May; 26(3):201-11. PubMed ID: 25714072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.
    Gurbel PA; Bliden KP; Guyer K; Cho PW; Zaman KA; Kreutz RP; Bassi AK; Tantry US
    J Am Coll Cardiol; 2005 Nov; 46(10):1820-6. PubMed ID: 16286165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of red cell distribution width with in-stent restenosis in patients with stable coronary artery disease.
    Kurtul A; Murat SN; Yarlioglues M; Duran M; Karadeniz M; Ergun G; Akyel A; Mendi MA; Oksuz F
    Platelets; 2015; 26(1):48-52. PubMed ID: 24831828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.
    Jeong YH; Bliden KP; Shuldiner AR; Tantry US; Gurbel PA
    Thromb Haemost; 2014 Apr; 111(4):713-24. PubMed ID: 24336898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
    Gurbel PA; Bliden KP; Guyer K; Aggarwal N; Tantry US
    Thromb Res; 2007; 119(5):563-70. PubMed ID: 16806409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between hyporesponsiveness to clopidogrel measured by thrombelastography and in stent restenosis in patients undergoing percutaneous coronary intervention.
    Fu Z; Dong W; Shen M; Xue H; Guo J; Jing J; Han Y; Yang X; Chen Y
    Clin Biochem; 2014 Nov; 47(16-17):197-202. PubMed ID: 25160657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up.
    Zhao C; Yang L; Mao L; Zhong L; Li X; Wei S
    Coron Artery Dis; 2013 Aug; 24(5):357-60. PubMed ID: 23835667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Treated with Percutaneous Coronary Intervention.
    Hu CP; Du Y; Zhu Y; Shi C; Qin Z; Zhao YX
    Chin Med J (Engl); 2018 Apr; 131(7):757-763. PubMed ID: 29578117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preprocedural red blood cell distribution width predicts bare metal stent restenosis.
    Yildiz A; Tekiner F; Karakurt A; Sirin G; Duman D
    Coron Artery Dis; 2014 Sep; 25(6):469-73. PubMed ID: 24614629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents.
    Gai MT; Zhu B; Chen XC; Liu F; Xie X; Gao XM; Ma X; Fu ZY; Ma YT; Chen BD
    Lipids Health Dis; 2021 Sep; 20(1):118. PubMed ID: 34587955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries.
    Shi KQ; Wu FL; Liu WY; Zhao CC; Chen CX; Xie YY; Wu SJ; Lin XF; Chen YP; Wong DK; Yuen MF; Zheng MH
    Mol Biol Rep; 2014 Jul; 41(7):4713-20. PubMed ID: 24691745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis.
    Jones GT; Tarr GP; Phillips LV; Wilkins GT; van Rij AM; Williams MJ
    Atherosclerosis; 2009 Dec; 207(2):603-7. PubMed ID: 19576586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship Between Lymphocyte-to-Monocyte Ratio and Bare-Metal Stent In-Stent Restenosis in Patients With Stable Coronary Artery Disease.
    Murat SN; Yarlioglues M; Celik IE; Kurtul A; Duran M; Kilic A; Oksuz F
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):235-240. PubMed ID: 26759373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.